NASDAQ: PHATPhathom Pharmaceuticals Inc Stock
$4.03-0.20 (-4.73%)
Updated Apr 17, 2025
PHAT Price
$4.03
Fair Value Price
$4.70
Market Cap
$280.64M
52 Week Low
$3.81
52 Week High
$19.71
P/E
-0.76x
P/B
-1.11x
P/S
9.29x
PEG
N/A
Dividend Yield
N/A
Revenue
$55.25M
Earnings
-$334.33M
Gross Margin
85.6%
Operating Margin
-474.76%
Profit Margin
-605.1%
Debt to Equity
-2.49
Operating Cash Flow
-$267M
Beta
1.42
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
PHAT Overview
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PHAT's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
PHAT
Ranked#304 of 463
Ranked#304 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important PHAT news, forecast changes, insider trades & much more!
PHAT News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PHAT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PHAT ($4.03) is undervalued by 14.21% relative to our estimate of its Fair Value price of $4.70 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
PHAT ($4.03) is not significantly undervalued (14.21%) relative to our estimate of its Fair Value price of $4.70 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PHAT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PHAT due diligence checks available for Premium users.
Valuation
PHAT fair value
Fair Value of PHAT stock based on Discounted Cash Flow (DCF)
Price
$4.03
Fair Value
$4.70
Undervalued by
14.21%
PHAT ($4.03) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PHAT ($4.03) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PHAT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PHAT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.76x
Industry
-177.72x
Market
27.98x
PHAT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-1.11x
Industry
4.05x
PHAT's financial health
Profit margin
Revenue
$29.7M
Net Income
-$74.5M
Profit Margin
-251%
PHAT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
PHAT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$378.3M
Liabilities
$631.9M
Debt to equity
-2.49
PHAT's short-term assets ($360.13M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PHAT's long-term liabilities ($546.17M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PHAT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PHAT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$63.5M
Investing
-$5.0k
Financing
$26.0M
PHAT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PHAT vs Biotech Stocks
Phathom Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.